Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 with Chemotherapy or Anlotinib in Perioperative NSCLC
NCT05913089Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2023; status: recruiting.
02
Drugs
benmelstobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05913089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913089.